A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis
The DOI matches its Crossref record.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only two RCTs were identified for NSAIDs, one of which evaluated rofecoxib 75 (now withdrawn from the market). The second RCT evaluated celecoxib in patients with CP/CPPS, with a statistically significant decrease in NIH‐CPSI total (P < 0.015), pain (P < 0.006) and QoL (P < 0.032) scores after 2, 4 and 6 weeks; however, the effects were limited to the short duration of therapy 76.”
From Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline (2015) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 19
- McNaughton Collins, 1998, How common is prostatitis? A national survey of physician visits, J Urol, 159, 1224, 10.1016/S0022-5347(01)63564-X · DOI · Paper page
- Mehik, 2000, Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study, BJU Int, 86, 443, 10.1046/j.1464-410X.2000.00836.x · DOI · Paper page
- Nickel, 2001, Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index, J Urol, 165, 842, 10.1016/S0022-5347(05)66541-X · DOI · Paper page
- Krieger, 1999, NIH consensus definition and classification of prostatitis, JAMA, 282, 236, 10.1001/jama.282.3.236 · DOI · Paper page
- Nickel, 1999, Prostatitis: evolving management strategies, Urol Clin North Am, 26, 737, 10.1016/S0094-0143(05)70215-9 · doi:10.1016/s0094-0143(05)70215-9
- O'Leary, 2001, Are there long term changes in symptoms over time in men with chronic prostatitis? An interim report from the Chronic Prostatitis Cohort (CPC) study, J Urol, 165, 24
- Nickel, 2001, The natural history of prostatitis-like symptoms: a population based study, J Urol, 165, 23
- McNaughton Collins, 2000, Diagnosis and treatment of chronic abacterial prostatitis: a systematic review, Ann Intern Med, 133, 367, 10.7326/0003-4819-133-5-200009050-00013 · DOI
- Donnelly, 1997, Review article: COX-II inhibitors—a new generation of safer NSAIDS?, Aliment Pharmacol Ther, 11, 227, 10.1046/j.1365-2036.1997.154330000.x · DOI
- Alexander, 1998, Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome, Urology, 52, 744, 10.1016/S0090-4295(98)00390-2 · DOI · Paper page
- Spaziani, 1996, The induction of cyclooxygenase-2 (COX-2) in intact human amnion tissue by interleukin-4, Prostaglandins, 51, 215, 10.1016/0090-6980(96)00005-6 · DOI
- Benaim, 2001, Correlation between the histological grade and COX-2 expression in prostate cancer, J Urol, 165, 240
- Madaan, 2000, Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment, BJU Int, 86, 736, 10.1046/j.1464-410x.2000.00867.x · DOI · Paper page
- Propert, 2002, Design of a multicenter randomized clinical trial for chronic prostatitis/chronic pelvic pain syndrome, Urology, 59, 870, 10.1016/S0090-4295(02)01601-1 · doi:10.1016/s0090-4295(02)01601-1
- Meares, 1968, Bacteriologic localization patterns in bacterial prostatitis and urethritis, Invest Urol, 5, 492
- Litwin, 1999, The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure, J Urol, 162, 369, 10.1016/S0022-5347(05)68562-X · DOI · Paper page
- Bellamy, 1997, Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand oseoarthritis. Consensus development at OMERACT III, J Rheumatol, 24, 799
- Barry, 1995, Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association, Med Care, 33, AS145
- Schaeffer, 2002, Leukocyte and bacterial counts do not correlate with severity of symptoms in men with chronic prostatitis: The National Institutes of Health Chronic Prostatitis Cohort Study, J Urol, 168, 1048, 10.1016/S0022-5347(05)64572-7 · DOI · Paper page
Cited by
Rees, J., Abrahams, M., Doble, A., Cooper, A., & the Prostatitis Expert Reference Group (PERG) (2015) · BJU International · doi:10.1111/bju.13101 · Cited by 371
Borgert, B. J., Wallen, E. M., & Pham, M. N. (2025) · JAMA · doi:10.1001/jama.2025.11499 · Cited by 50
Doiron, R. C., Tripp, D. A., Tolls, V., & Nickel, J. C. (2018) · Canadian Urological Association Journal · doi:10.5489/cuaj.4876 · Cited by 24
Self-citation
Metadata
- Authors
- NICKEL, J. C., PONTARI, M., MOON, T., GITTELMAN, M., MALEK, G., FARRINGTON, J., PEARSON, J., KRUPA, D., BACH, M., DRISKO, J., & THE ROFECOXIB PROSTATITIS INVESTIGATOR TEAM
- Affiliations
- From the Department of Urology, Queen’s University, Kingston General Hospital, Kingston, Ontario, Canada, the Department of Urology, Temple University School of Medicine, Philadelphia, Pennsylvania, University of Wisconsin Medical School and Jackson Foundation, Madison, Wisconsin, South Florida Medical Center, Aventura, Florida, and Merck Research Laboratories, Rahway, New Jersey
- Venue
- Journal of Urology
- Published
- 2003-04
- Volume
- 169
- Issue
- 4
- Pages
- 1401-1405
- ISSN
- 0022-5347
- 1527-3792
- Cited by
- 120
- References
- 0
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis. https://app.cochat.ai/papers/10.1097/01.ju.0000054983.45096.16
- The paper
- NICKEL, J. C., PONTARI, M., MOON, T., GITTELMAN, M., MALEK, G., FARRINGTON, J., PEARSON, J., KRUPA, D., BACH, M., DRISKO, J., & THE ROFECOXIB PROSTATITIS INVESTIGATOR TEAM. (2003). A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis. Journal of Urology. https://doi.org/10.1097/01.ju.0000054983.45096.16
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.